{
  "abstract": "Background and Importance Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder that significantly impacts both physical and psychological well-being. Adalimumab was the first biologic approved for HS, with newer agents such as secukinumab and bimekizumab targeting the IL-17 pathway. Adherence and persistence to treatment are crucial for ensuring therapeutic efficacy and optimising health outcomes in hospital pharmacy settings.Aim and Objectives To describe the profile of patients with HS treated with adalimumab, secukinumab, or bimekizumab, and to assess the persistence of these biologic therapies in a tertiary care hospital.Material and Methods This is a retrospective, observational, single-centre study of patients treated with biologics (adalimumab, secukinumab, or bimekizumab) for HS from 5 August 2015, to 29 August 2025. Data collected included: sex, age, treatment initiation and cessation dates, reason for treatment change, and adherence (defined as a possession rate ≥90% based on dispensing records).Results A total of 119 patients with a mean age of 44 ± 12.0 years were included; 74 (62.2%) were male.Of these, 81 (68.1%) were on their first-line of treatment, 36 (30.3%) had received two lines, and 2 (1.7%) had received three lines due to ineffectiveness or lack of response.Currently, 75 patients (63.0%) are on adalimumab, 39 (32.8%) on secukinumab, and five (4.2%) on bimekizumab. Among those on adalimumab, 96.0% follow a weekly regimen, while 4.0% receive it biweekly; 53.8% of patients on secukinumab follow a monthly regimen, 38.5% biweekly, and 7.7% weekly. Of the bimekizumab patients, three follow a biweekly regimen, one a monthly regimen, and one a bimonthly regimen.Adherence rates were high for adalimumab (86.6%), secukinumab (97.7%), and bimekizumab (80.0%).The median persistence for adalimumab was 441 days (95% CI 299.6-582.4), secukinumab 245 days (95% CI 171.3-318.7), and bimekizumab 190 days (95% CI 13.1-458.4).Conclusion and Relevance Adalimumab remains the most widely used and persistent treatment, while secukinumab stands out for its high adherence. These findings highlight the importance of hospital pharmacy monitoring to optimise patient outcomes and inform clinical decision making in biologic therapy selection.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "R Simal López"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "A Pinilla Rello"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "M Pérez Huerga"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "E Chilet Rodrigo"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Dermatology, Zaragoza, Spain"
      ],
      "name": "S De La Fuente Meira"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "E Fernández Alonso"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "M Gimeno Gracia"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "I Navarro Pardo"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "MÁ Allende Bandrés"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "JR Lozano Ortiz"
    },
    {
      "affiliations": [
        "Hospital Clínico Universitario Lozano Blesa, Pharmacy, Zaragoza, Spain"
      ],
      "name": "T Salvador Gómez"
    }
  ],
  "title": "4CPS-177 Real-world use, persistence, and adherence to biologic therapies in hidradenitis suppurativa",
  "uid": "35f78934-595d-572d-ab19-3ed30ab00f8e"
}